As for Exubera®, it was the first of its kind, rapid-acting regular human insulin administered by oral inhalation before meals, approved in January 2006 by the FDA and European Commission (EC) as the therapy in adults with types 1 and 2 diabetes mellitus [167,168]. This evidence concerns the gene INS and diabetes mellitus.